Publication:
Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?

Simple item page
dc.contributor.authorGÜMÜŞ, MAHMUT
dc.contributor.authorOven, Basak Bala
dc.contributor.authorAtci, Muhammed Mustafa
dc.contributor.authorARIKAN, RUKİYE
dc.contributor.authorAy, Seval
dc.contributor.authorAyhan, Murat
dc.contributor.authorSelvi, Oguzhan
dc.contributor.authorOzyukseler, Deniz Tataroglu
dc.contributor.authorBayram, Ertugrul
dc.contributor.authorÖZCAN, ERKAN
dc.contributor.authorYASİN, Ayşe İrem
dc.contributor.institutionauthorYASİN, AYŞE İREM
dc.date.accessioned2022-06-14T20:59:08Z
dc.date.available2022-06-14T20:59:08Z
dc.date.issued2022-05-01T00:00:00Z
dc.description.abstractBackground Triple-negative-breast-cancer (TNBC) has a poor prognosis if pathologic complete response (pCR) cannot be achieved following neoadjuvant chemotherapy (NAC). The group of patients that benefit most from adjuvant capecitabine remains unclear. Materials and Methods We analyzed data of 160 consecutive patients with residual TNBC from eight cancer-center. Pathologic response was defined into two groups as having good-pathologic-response (MillerPayneGrading (MPG) IV-III) or poor-pathologic-response (MPG I-II). The characteristics of patients were compared regarding adjuvant capecitabine usage. Results Univariate-analysis revealed that age, histology, clinical-stage, tumor-size, lymph-nodes number, menopausal status, and pathological-stage were significantly different between two groups. In multivariate-analysis, menopausal status (p = 0.043) and residual tumor-size (p < 0.001) were found to be independent prognostic factors for pathological response. The hazard-ratio for disease recurrence and death in the poor-response group with adjuvant capecitabine was 2.94 (95% confidence-interval (CI), 1.21 to 7.10; p = 0.016) and 4.080 (95% CI, 1.22 to 13.64; p = 0.022), respectively. DFS (p = 0.58) and OS (p = 0.89) improvements with adjuvant capecitabine were not demonstrated in good-response groups. Conclusion This multicenter-study suggested that only the poor-response group to NAC achieved benefit from adjuvant capecitabine. Postmenopausal status and residual tumor-size were related to poor prognosis.
dc.identifier.citationDulgar O., Oven B. B. , Atci M. M. , ARIKAN R., Ay S., Ayhan M., Selvi O., Ozyukseler D. T. , Bayram E., ÖZCAN E., et al., -Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?-, EXPERT REVIEW OF ANTICANCER THERAPY, 2022
dc.identifier.doi10.1080/14737140.2022.2076670
dc.identifier.pubmed35543015
dc.identifier.scopus85131384593
dc.identifier.urihttp://hdl.handle.net/20.500.12645/30742
dc.identifier.wosWOS:000804681400001
dc.titleIs the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?
dc.typeArticle
dspace.entity.typePublication
local.avesis.id2669f7c1-a2aa-4d0b-b3d2-f4b1d0689a5c
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublicationdc78f073-a262-42b7-893f-38dcc921fdbb
relation.isAuthorOfPublication.latestForDiscoverydc78f073-a262-42b7-893f-38dcc921fdbb
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Collections
Yayınlar - Eserler